AlaviA.HamzaviI.BrownKet al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803-813.doi:10.1111/bjd.2096934978076
2.
SchellSL.CongZ.SennettMLet al. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies. Br J Dermatol. 2023;188(3):407-419.doi:10.1093/bjd/ljac09636680309
3.
JohnstonLA.AlhusayenR.BourcierMet al. Practical guidelines for managing patients with hidradenitis suppurativa: an update. J Cutan Med Surg. 2022;26(2_suppl):2S-24.doi:10.1177/1203475422111611536000460
4.
AbbVie. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa. clinicaltrials.gov; 2023. Accessed April 19, 2023. https://clinicaltrials.gov/ct2/show/NCT04430855
5.
Incyte Corporation. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa. clinicaltrials.gov; 2023. Accessed April 19, 2023. https://clinicaltrials.gov/ct2/show/results/NCT04476043
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
